CELLTRION
Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (“Takeda”) in Asia Pacific, igniting efforts to strengthen its R&D capability in the global small molecule pharmaceuticals business.
In June, the firms announced an agreement under which Celltrion would acquire 18 "Primary Care" product assets in the Asia Pacific area for a total of USD 278 million inclusive of milestone payments from Takeda. Celltrion proceeded with the acquisition process through its newly established subsidiary in Singapore, "Celltrion Asia Pacific Pte, Ltd."1 ("Celltrion APAC").
Upon completion of the acquisition, Celltrion APAC will assume the ownership of the rights to patents, trademarks, and sales of 18 products sold in 9 markets including South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia.
The 18 products include prescription medicines such as Nesina (diabetes), Actos (diabetes), and Edarbi (hypertension) which were developed for global market, as well as OTC (Over-the-counter) products well known to consumers such as Whituben (cold remedy). Nesina and Edarbi in particular are expected to contribute to a stable revenue growth as the product patents will be protected until 2026 and 2027, respectively.
Celltrion Pharm, a Celltrion subsidiary, will be a primary domestic distributor, while Celltrion Healthcare will distribute internationally, leveraging its sales networks in Southeast Asia and Australia. Celltrion has entered into a manufacturing and supply agreement with Takeda who will continue to manufacture the divested products for stable product supply and some of the products for local and international market will be manufactured at Celltrion Pharm’s cGMP production facilities in future.
The acquisition provides Celltrion group an opportunity to strengthen its small molecule pharmaceutical product portfolio and progress towards a market leading position as a global biopharmaceutical company.
Celltrion group also expects this transaction to help position itself as a stable supplier of high-quality, made-in-Korea original drugs and contribute to the reinforced financial strength of the national health system.
Based on its own R&D capacities and to-be acquired product patents, Celltrion plans to speed up the development of new medicines such as extended-release drugs and compound drugs, as well as biosimilar insulins to complete the portfolio of diabetic and hypertensive pipelines.
Celltrion CEO Kee Woosung said "With the successful acquisition of select primary care and OTC product assets from Takeda in Asia Pacific Celltrion has set an important opportunity to develop additional new drugs and expand its market share in the region," and "Celltrion will also do its best to secure a leading position in the Asia Pacific market and provide high quality medical products in the region."
About Celltrion, Inc
Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for Inflectra® and Remsima®, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. Also Celltrion received FDA and EC’s approval for Truxima® and Herzuma®. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines.
1 Celltrion Asia Pacific PtE. Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005459/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy Adds Dynamic Rate Management for EI Residential Solar-Plus-Storage Solution in EU9.12.2025 05:00:00 CET | Press release
Tigo EI Residential solar-plus-storage solution moves with real-world demand through a new smart feature that maximizes savings and grid independence. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced the addition of Dynamic Rate Management to the Tigo EI Residential solar-plus-storage solution. This new capability enables Tigo all-in-one ecosystem to intelligently respond dynamically to changes in electricity rates. This addition of Dynamic Rate Management comes at a time when European energy companies are rapidly expanding the use of dynamic rates across several EU nations. The Dynamic Rate Manager will be available for new Tigo EI customers as well as existing EI Residential system owners as a part of a software update with no additional hardware, accessories, or configuration required. The Dynamic Rate Management feature allows the EI Residential solution to automatically acquire and interp
SII Begins Mass Production of the World’s Smallest (1.0 × 0.8 × 0.32mm) Tuning-Fork Crystal Resonator “SC-10S”9.12.2025 03:00:00 CET | Press release
Achieving Both a 33% Reduction in Mounting Area and Low ESR Seiko Instruments Inc. (President: Yoichi Endo; Headquarters: Chiba City, Chiba Prefecture; hereinafter “SII”) will begin mass production of the “SC-10S” (32.768kHz), the world’s smallest* tuning-fork crystal resonator measuring 1.0 × 0.8mm, starting in April 2026. *Based on SII research as of November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202800779/en/ Product Image-1 [Background of Development] SII has already been mass-producing the “SC-12S” (32.768kHz), one of the world’s smallest tuning-fork crystal resonators at 1.2 × 1.0mm. As wearable devices such as smart rings and smartwatches, as well as IoT devices, continue to become smaller, the electronic components built into these devices are increasingly required to support high-density mounting, low power consumption, and high performance. To meet these needs, SII leveraged its proprietary photol
Verimatrix: Signing of an Agreement for the Sale of XTD Assets (Code and Application Protection) to Guardsquare8.12.2025 17:45:00 CET | Press release
Sale of XTD assets (mobile application protection) including a portfolio of patents and a team of experts for an initial offer of $8.5m, the final price will be adjusted at the closing.Verimatrix refocuses on Anti-Piracy (video protection), the group's core business representing approximately 90% of its total revenue Regulatory News: VERIMATRIX (Euronext Paris: VMX, FR0010291245), a leading provider of user security solutions for a safer connected world, announces the signing of an agreement with Belgium-based Guardsquare, the leading provider of mobile application security, for the sale of its Extended Threat Defense (XTD) assets. Guardsquare, the creators of the open-source optimization tool, ProGuard, offers the most complete mobile application security platform on the market spanning automated testing and multi-layered protection, real time threat monitoring, and app attestation. Guardsquare’s 975+ customers are located in more than 95 countries and represent all major industries.
WNBA Champion Sabrina Ionescu Becomes Global Brand Ambassador for Ant International8.12.2025 17:00:00 CET | Press release
Four-time WNBA All-Star Sabrina Ionescu today becomes a new Global Brand Ambassador for Ant International, a leading global provider of digital payments, digitisation, and financial technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208536426/en/ The partnership is built on a shared commitment to creating a more inclusive and sustainable world through empowering underserved communities and youth groups with sports and technology innovation. It marks an important step in Ant International’s journey to foster growth and expand access to financial tools through innovative technology. Ionescu serves as the first Ant International global brand ambassador from North America. “Sabrina embodies the spirit of perseverance and the passion for excellence that is driving young talents and small businesses around the world to uplift their communities,” said Douglas Feagin, President of Ant International. “As a legend in a spor
SABCS 2025: REVEAL GENOMICS Presents Major Advance in Predicting Brain Metastasis in HER2+ Breast Cancer8.12.2025 16:20:00 CET | Press release
The new HER2DX central nervous system (CNS) progression score predicts risk of brain progression in advanced HER2+ breast cancer, addressing a major unmet need in identifying patients at the highest risk of CNS involvement. During SABCS 2025, the company presents a total of 7 studies with 1,300 tumor samples analyzed, covering HER2-positive, ER-negative, and triple-negative breast cancer (TNBC), representing one of the largest and most comprehensive genomic data contributions to the symposium. New clinical evidence includes superior pCR prediction compared with TILs, demonstration of real-time genomic testing feasibility in an international trial, and validation of RNA-based ERBB2 assessment to accelerate clinical decision-making. REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company focused on advancing precision oncology through biomarker innovation, announced today the presentation of seven studies at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2025, held Decem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom